TimesSquare Capital Management’s United Therapeutics UTHR Stock Holding History

TimesSquare Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,200	Closed	-$334K	–	191
2022 Q4	$334K	Buy	+1,200	New	+$303K	﹤0.01%	176
2015 Q3	–	Sell	-95,000	Closed	-$16.5M	–	257
2015 Q2	$16.5M	Sell	95,000 -776,950	-89%	-$140M	0.09%	218
2015 Q1	$150M	Sell	871,950 -128,050	-13%	-$19.5M	0.81%	27
2014 Q4	$129M	Sell	1,000,000 -66,000	-6%	-$8.51M	0.72%	34
2014 Q3	$137M	Sell	1,066,000 -242,900	-19%	-$25M	0.78%	31
2014 Q2	$116M	Buy	1,308,900 +637,500	+95%	+$61.3M	0.62%	44
2014 Q1	$63.1M	Buy	671,400 +231,945	+53%	+$23.7M	0.33%	113
2013 Q4	$49.7M	Sell	439,455 -48,950	-10%	-$4.41M	0.25%	144
2013 Q3	$38.5M	Sell	488,405 -17,890	-4%	-$1.31M	0.22%	170
2013 Q2	$33.3M	Buy	+506,295	New	+$32.6M	0.21%	167

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

TimesSquare Capital Management's UTHR Position: Q1 2023 in Review

TimesSquare Capital Management sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 1,200 shares — an estimated $334K sold.

TimesSquare Capital Management first reported a position in UTHR in Q2 2013 and held it in 10 quarters. The position peaked at $150M in Q1 2015. 505 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

TimesSquare Capital Management reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
TimesSquare Capital Management sold 1,200 United Therapeutics shares in Q1 2023, an estimated $334K.
TimesSquare Capital Management first reported a position in United Therapeutics in Q2 2013 and held it in 10 quarters.
TimesSquare Capital Management's United Therapeutics position peaked at $150M in Q1 2015.
505 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on TimesSquare Capital Management's 13F filing for Q1 2023, filed 10 May 2023.